| Name | Title | Contact Details |
|---|
We`re on a mission to make life better for patients taking part in clinical trials around the world, and their caregivers. Our solutions focus on the four key elements of a successful clinical trial: recruitment, engagement, retention and trial outcomes. Combining our in-house technology platforms with 24/7 truly personalised patient care, we focus on creating remarkable patient experiences at every stage of the clinical journey. Remarkable means going above and beyond to support patients in a way that works best for them and their lives. Whether that`s facilitating clinical trial participation in their own homes, supporting them to travel safely to and from study sites, or using technology to manage everything from expense reimbursement to telehealth, we work with our partners to support the protocol design that meets their patient`s needs. Understanding the complexities of the patient journey is paramount to advancing medicine, and exploring digital technology that enables better trial outcomes has never been more important. This all starts with putting patients first in clinical research. When you partner with us, your patients receive a truly remarkable service and your trial outcomes are better.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Alcoholics Anonymous Dist 21 is a Methuen, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Catasys leads the health care industry in improving health and reducing claims costs for health plan members with behavioral health disorders that cause or exacerbate co-existing medical conditions. OnTrak™, a 52-week intensive outpatient program, treats an overlooked population: members suffering from chronic disorders such as substance dependence, anxiety and depression who rarely seek care. These members cost health plans millions of medical dollars primarily due to preventable ambulance usage, medical ER visits and medical inpatient admissions. Catasys uses a proprietary analytics platform and predictive modeling to identify high utilizers of medical healthcare services with costs that can be significantly reduced by addressing the underlying behavioral health disorder(s). Through proactive outreach, we engage and treat these individuals in our patient-centric program that integrates evidence-based medical interventions, psychosocial skill building and care coaching by nurses.
Mount Sinai New York University Health is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Mount Sinai New York University Health, please visit www.msnyuhealth.org